carvedilol has been researched along with Cardiotoxicity in 27 studies
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an early decrease in LVEF." | 9.41 | Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. ( Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ, 2021) |
| "We designed a pilot, randomized controlled, two-arm clinical trial with 32 patients to evaluate the effects of non-hypoxic cardiac preconditioning (DHA) plus carvedilol on subclinical cardiotoxicity in breast cancer patients undergoing anthracycline treatment." | 9.34 | Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled tria ( Aguayo, R; Carrasco, R; Cortés, I; Erazo, M; Gormaz, JG; Hasson, D; Henriquez, P; Morales, M; Nes, K; Ramirez, MC; Ramos, C; Salas, C; Schuster, A; Sotomayor, CG, 2020) |
| "This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity." | 9.27 | Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. ( Abduch, MC; Avila, MS; Ayub-Ferreira, SM; Bittencourt Viana Cruz, CB; Bittencourt, MS; Bocchi, EA; das Dores Cruz, F; de Barros Wanderley, MR; de Paula Costa, RL; Ferrari, MSM; Gonçalves Brandão, SM; Guimaraes, GV; Hajjar, LA; Higuchi-Dos-Santos, MH; Hoff, PM; Issa, VS; Kalil Filho, R; Lofrano Alves, MS; Mano, MS; Rigaud, VOC; Sahade, M, 2018) |
| "We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy." | 9.24 | Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. ( Fink, A; Guglin, M; Krischer, J; Munster, P, 2017) |
| "In this randomized, single-blind, placebo-controlled study, 91 women with recently diagnosed breast cancer undergoing ANT therapy were randomly assigned to groups treated with either carvedilol (n = 46) or placebo (n = 45)." | 9.24 | Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. ( Baghyari, S; Esmaili, K; Janbabai, G; Nabati, M; Yazdani, J, 2017) |
| "In this trial, 70 female patients with breast cancer who were candidates to receive doxorubicin were enrolled, from which 30 were selected randomly to receive carvedilol 6." | 9.22 | Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial. ( Fazlinezhad, A; Homaei Shandiz, F; Hosseini, G; Mostafavi Toroghi, H; Tashakori Beheshti, A; Zarifian, A, 2016) |
| " Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy." | 7.96 | In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020) |
| "Cadmium (Cd) is a highly toxic heavy metal with several harmful effects including cardiotoxicity." | 7.91 | Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway. ( Bayoumi, AMA; El-Hussieny, M; Refaie, MMM; Shehata, S, 2019) |
| "In this study, we tried to demonstrate the effects of adding human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) to carvedilol in improving the doxorubicin- induced cardiotoxicity in rats." | 7.88 | Umbilical cord blood-mesenchymal stem cells and carvedilol reduce doxorubicin- induced cardiotoxicity: Possible role of insulin-like growth factor-1. ( Abbas, NAT; Abdel Aal, SM; Mousa, HSE, 2018) |
| " Patients at high risk of cardiotoxicity (cardiac troponin I concentrations in the upper tertile during chemotherapy) were randomized to standard care plus cardioprotection (combination carvedilol and candesartan therapy) or standard care alone." | 5.69 | Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. ( Borley, A; Broom, A; Collins, G; Eddie, L; Everett, RJ; Fletcher, A; Guppy, A; Hall, P; Henriksen, PA; Japp, A; Joshi, SS; Lang, NN; Lewis, S; Lord, S; Maclean, M; MacPherson, IR; McKay, P; McVicars, H; Mills, NL; Newby, DE; Oikonomidou, O; Payne, JR; Primrose, L; Radford, J; Rodriguez, A; Rowntree, C; Singh, T; Stavert, H; Williams, MC, 2023) |
| "Carvedilol (CAR) is a β-blocker used to treat high blood pressure and heart failure." | 5.51 | Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. ( Yang, JJ; Zhang, HS; Zhang, QL, 2019) |
| "Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an early decrease in LVEF." | 5.41 | Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. ( Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ, 2021) |
| "We designed a pilot, randomized controlled, two-arm clinical trial with 32 patients to evaluate the effects of non-hypoxic cardiac preconditioning (DHA) plus carvedilol on subclinical cardiotoxicity in breast cancer patients undergoing anthracycline treatment." | 5.34 | Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled tria ( Aguayo, R; Carrasco, R; Cortés, I; Erazo, M; Gormaz, JG; Hasson, D; Henriquez, P; Morales, M; Nes, K; Ramirez, MC; Ramos, C; Salas, C; Schuster, A; Sotomayor, CG, 2020) |
| "This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity." | 5.27 | Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. ( Abduch, MC; Avila, MS; Ayub-Ferreira, SM; Bittencourt Viana Cruz, CB; Bittencourt, MS; Bocchi, EA; das Dores Cruz, F; de Barros Wanderley, MR; de Paula Costa, RL; Ferrari, MSM; Gonçalves Brandão, SM; Guimaraes, GV; Hajjar, LA; Higuchi-Dos-Santos, MH; Hoff, PM; Issa, VS; Kalil Filho, R; Lofrano Alves, MS; Mano, MS; Rigaud, VOC; Sahade, M, 2018) |
| "We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy." | 5.24 | Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. ( Fink, A; Guglin, M; Krischer, J; Munster, P, 2017) |
| "In this randomized, single-blind, placebo-controlled study, 91 women with recently diagnosed breast cancer undergoing ANT therapy were randomly assigned to groups treated with either carvedilol (n = 46) or placebo (n = 45)." | 5.24 | Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. ( Baghyari, S; Esmaili, K; Janbabai, G; Nabati, M; Yazdani, J, 2017) |
| "Cardiac CARE will examine whether cardiac biomarker monitoring identifies patients at risk of left ventricular dysfunction following anthracycline chemotherapy and whether troponin-guided treatment with combination candesartan and carvedilol therapy prevents the development of left ventricular dysfunction in these high-risk patients." | 5.22 | Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. ( Borley, A; Broom, A; Collins, G; Guppy, A; Hall, P; Henriksen, PA; Lang, NN; Lewis, S; Lord, S; Maclean, M; MacPherson, IR; McKay, P; McVicars, H; Mills, NL; Newby, DE; Oikonomidou, O; Payne, JR; Radford, J; Rowntree, C; Scott, F, 2022) |
| "In this trial, 70 female patients with breast cancer who were candidates to receive doxorubicin were enrolled, from which 30 were selected randomly to receive carvedilol 6." | 5.22 | Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial. ( Fazlinezhad, A; Homaei Shandiz, F; Hosseini, G; Mostafavi Toroghi, H; Tashakori Beheshti, A; Zarifian, A, 2016) |
| " Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy." | 3.96 | In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020) |
| "Cadmium (Cd) is a highly toxic heavy metal with several harmful effects including cardiotoxicity." | 3.91 | Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway. ( Bayoumi, AMA; El-Hussieny, M; Refaie, MMM; Shehata, S, 2019) |
| "In this study, we tried to demonstrate the effects of adding human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) to carvedilol in improving the doxorubicin- induced cardiotoxicity in rats." | 3.88 | Umbilical cord blood-mesenchymal stem cells and carvedilol reduce doxorubicin- induced cardiotoxicity: Possible role of insulin-like growth factor-1. ( Abbas, NAT; Abdel Aal, SM; Mousa, HSE, 2018) |
| " To tackle this issue, we established embryonic zebrafish models of doxorubicin-, adrenaline- and terfenadine-induced cardiotoxicity with unified dosing regimen which eventually enabled head-to-head comparison of the drugs." | 1.72 | Pharmacological assessment of zebrafish-based cardiotoxicity models. ( Maciag, M; Mierzejewska, M; Plazinska, A; Wnorowski, A, 2022) |
| "Carvedilol (CAR) is a β-blocker used to treat high blood pressure and heart failure." | 1.51 | Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. ( Yang, JJ; Zhang, HS; Zhang, QL, 2019) |
| "Cardiotoxicity is associated with the chronic use of doxorubicin leading to cardiomyopathy and heart failure." | 1.46 | Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. ( Alves, MS; Ávila, MS; Ayub-Ferreira, SM; Bocchi, EA; Brandão, SM; Cruz, CB; Cruz, FD; Cunha-Neto, E; Ferreira, LR; Guimarães, GV; Issa, VS; Rigaud, VO; Santos, MH, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (66.67) | 24.3611 |
| 2020's | 9 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Maciag, M | 1 |
| Wnorowski, A | 1 |
| Mierzejewska, M | 1 |
| Plazinska, A | 1 |
| Henriksen, PA | 2 |
| Hall, P | 2 |
| Oikonomidou, O | 2 |
| MacPherson, IR | 2 |
| Maclean, M | 2 |
| Lewis, S | 2 |
| McVicars, H | 2 |
| Broom, A | 2 |
| Scott, F | 1 |
| McKay, P | 2 |
| Borley, A | 2 |
| Rowntree, C | 2 |
| Lord, S | 2 |
| Collins, G | 2 |
| Radford, J | 2 |
| Guppy, A | 2 |
| Payne, JR | 2 |
| Newby, DE | 2 |
| Mills, NL | 2 |
| Lang, NN | 2 |
| Mohamed, RMSM | 1 |
| Ahmad, EA | 1 |
| Omran, BHF | 1 |
| Sakr, AT | 1 |
| Ibrahim, IAAE | 1 |
| Mahmoud, MF | 1 |
| El-Naggar, ME | 1 |
| Joshi, SS | 1 |
| Singh, T | 1 |
| Rodriguez, A | 1 |
| Fletcher, A | 1 |
| Everett, RJ | 1 |
| Stavert, H | 1 |
| Eddie, L | 1 |
| Primrose, L | 1 |
| Williams, MC | 1 |
| Japp, A | 1 |
| Sun, J | 1 |
| Shang, H | 1 |
| Yang, X | 1 |
| Xing, Y | 1 |
| Ozkalayci, F | 1 |
| Tanboga, IH | 1 |
| Carrasco, R | 1 |
| Ramirez, MC | 1 |
| Nes, K | 1 |
| Schuster, A | 1 |
| Aguayo, R | 1 |
| Morales, M | 1 |
| Ramos, C | 1 |
| Hasson, D | 1 |
| Sotomayor, CG | 1 |
| Henriquez, P | 1 |
| Cortés, I | 1 |
| Erazo, M | 1 |
| Salas, C | 1 |
| Gormaz, JG | 1 |
| Beiranvand, E | 1 |
| Ostad, SN | 1 |
| Ardakani, EM | 1 |
| Torkashvand, F | 1 |
| Sardari, S | 1 |
| Vaziri, B | 1 |
| Alanazi, A | 1 |
| Fadda, L | 1 |
| Alhusaini, A | 1 |
| Ahmad, R | 1 |
| Lee, M | 1 |
| Chung, WB | 1 |
| Lee, JE | 1 |
| Park, CS | 1 |
| Park, WC | 1 |
| Song, BJ | 1 |
| Youn, HJ | 1 |
| Guglin, M | 1 |
| Munster, P | 1 |
| Fink, A | 1 |
| Krischer, J | 1 |
| Avila, MS | 3 |
| Ayub-Ferreira, SM | 2 |
| de Barros Wanderley, MR | 1 |
| das Dores Cruz, F | 1 |
| Gonçalves Brandão, SM | 1 |
| Rigaud, VOC | 1 |
| Higuchi-Dos-Santos, MH | 1 |
| Hajjar, LA | 1 |
| Kalil Filho, R | 1 |
| Hoff, PM | 1 |
| Sahade, M | 1 |
| Ferrari, MSM | 1 |
| de Paula Costa, RL | 1 |
| Mano, MS | 1 |
| Bittencourt Viana Cruz, CB | 1 |
| Abduch, MC | 1 |
| Lofrano Alves, MS | 1 |
| Guimaraes, GV | 2 |
| Issa, VS | 2 |
| Bittencourt, MS | 1 |
| Bocchi, EA | 3 |
| Mousa, HSE | 1 |
| Abdel Aal, SM | 1 |
| Abbas, NAT | 1 |
| Galderisi, M | 1 |
| Sorrentino, R | 1 |
| Esposito, R | 1 |
| Ayub Ferreira, SM | 1 |
| Kheiri, B | 1 |
| Abdalla, A | 1 |
| Osman, M | 1 |
| Haykal, T | 1 |
| Chahine, A | 1 |
| Ahmed, S | 1 |
| Osman, K | 1 |
| Hassan, M | 1 |
| Bachuwa, G | 1 |
| Bhatt, DL | 1 |
| Zhang, QL | 1 |
| Yang, JJ | 1 |
| Zhang, HS | 1 |
| Huang, S | 1 |
| Zhao, Q | 1 |
| Yang, ZG | 1 |
| Diao, KY | 1 |
| He, Y | 1 |
| Shi, K | 1 |
| Shen, MT | 1 |
| Fu, H | 1 |
| Guo, YK | 1 |
| Zhan, T | 1 |
| Daniyal, M | 1 |
| Li, J | 1 |
| Mao, Y | 1 |
| Barbosa, RR | 1 |
| Bourguignon, TB | 1 |
| Torres, LD | 1 |
| Arruda, LS | 1 |
| Jacques, TM | 1 |
| Serpa, RG | 1 |
| Calil, OA | 1 |
| Barbosa, LFM | 1 |
| Refaie, MMM | 1 |
| El-Hussieny, M | 1 |
| Bayoumi, AMA | 1 |
| Shehata, S | 1 |
| Barac, A | 1 |
| Blaes, A | 1 |
| Lynce, F | 1 |
| Tashakori Beheshti, A | 1 |
| Mostafavi Toroghi, H | 1 |
| Hosseini, G | 1 |
| Zarifian, A | 1 |
| Homaei Shandiz, F | 1 |
| Fazlinezhad, A | 1 |
| El-Shitany, NA | 1 |
| El-Desoky, K | 1 |
| Armenian, SH | 1 |
| Hudson, MM | 1 |
| Chen, MH | 1 |
| Colan, SD | 1 |
| Lindenfeld, L | 1 |
| Mills, G | 1 |
| Siyahian, A | 1 |
| Gelehrter, S | 1 |
| Dang, H | 1 |
| Hein, W | 1 |
| Green, DM | 1 |
| Robison, LL | 1 |
| Wong, FL | 1 |
| Douglas, PS | 1 |
| Bhatia, S | 1 |
| Rigaud, VO | 1 |
| Ferreira, LR | 1 |
| Brandão, SM | 1 |
| Cruz, FD | 1 |
| Santos, MH | 1 |
| Cruz, CB | 1 |
| Alves, MS | 1 |
| Cunha-Neto, E | 1 |
| Nabati, M | 1 |
| Janbabai, G | 1 |
| Baghyari, S | 1 |
| Esmaili, K | 1 |
| Yazdani, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)[NCT06005259] | Phase 4 | 264 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity. A Randomized Double Blind Study.[NCT01724450] | Phase 3 | 200 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Can Bisoprolol Administration Prevent Anthracycline-induced Cardiotoxicity?: a Double-blind Randomized Trial.[NCT05175066] | Phase 3 | 80 participants (Actual) | Interventional | 2020-11-12 | Completed | ||
| Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial[NCT02717507] | Phase 2 | 196 participants (Actual) | Interventional | 2016-04-04 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of pills taken out of the total prescribed in a 3-month period, averaged across all study time points. The proportion of participants with average adherence rate >90% is computed by arm and corresponding 95% confidence intervals are reported. (NCT02717507)
Timeframe: Average adherence across 6 months, 12 months, 18 months, 24 months after treatment initiation are calculated.
| Intervention | proportion of participants (Number) |
|---|---|
| Arm I (Carvedilol) | 0.483 |
| Arm II (Placebo) | 0.517 |
Patients with toxicities reported via CTEP-AERS and all Grade ≥ 2 adverse events (AEs) that can be attributed probably or definitely to the study drug are considered to have AEs. The proportion of patients with AEs are reported by arm with corresponding 95% confidence intervals. (NCT02717507)
Timeframe: From baseline to month 24 since baseline
| Intervention | Proportion of patients with AE (Number) |
|---|---|
| Arm I (Carvedilol) | 0.0267 |
| Arm II (Placebo) | 0 |
"In a questionnaire, patients responded Yes/No to certain symptoms. If answered Yes, they selected slightly, moderately, quite a bit, or extremely regarding how bothersome the symptom was. The proportion of participants responding with any of these three categories was calculated by arm, and corresponding 95% confidence intervals are reported." (NCT02717507)
Timeframe: responses at days 14 to 730 were combined
| Intervention | Proportion of patients (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | Skin rash | Itchy skin | Dry Mouth | Easy bruising | Nosebleeds | Sunburn easily | Weight gain | Fluid retention | Swollen feet | Increased sweating | Feeling weak in parts of your body | Shortness of breath or wheezing | Chest pain or heaviness | Heart racing or skipping beats | Feeling shaky or having tremors | Decreased bodily movement | Feeling nervous | Feeling downhearted, sad, and/or tearful | Mood swings | Dizziness and/or lightheadedness | Dizziness upon standing (from sitting or lying down) | Insomnia | Difficulty concentrating | Interrupted sleep | Tendency to take naps | TiredwheezingFeeling unusually tired | Falling asleep at inappropriate times | Ringing in the ears | Difficulty breathing | Sensation that I have to urinate much of the time | Discoloration of urine (ie, bloody) | Decreased libido | Unusually heavy menstrual flows (N/A if postmenopausal or male) | |
| Arm I (Carvedilol) | 0.0533 | 0.0933 | 0.1467 | 0.0667 | 0.0133 | 0.0667 | 0.0933 | 0.0533 | 0.0267 | 0 | 0.0933 | 0.0933 | 0.0933 | 0.08 | 0.08 | 0.0533 | 0.0133 | 0.1467 | 0.2 | 0.12 | 0.16 | 0.1467 | 0.1733 | 0.1067 | 0.2 | 0.12 | 0.2267 | 0.0267 | 0.0533 | 0.0267 | 0.0667 | 0 | 0.0667 | 0.2 |
| Arm II (Placebo) | 0.1316 | 0.0789 | 0.1447 | 0.1711 | 0.0921 | 0.0526 | 0.0526 | 0.0789 | 0.0395 | 0.0921 | 0.0789 | 0.1316 | 0.0395 | 0.0921 | 0.0395 | 0.0789 | 0.0395 | 0.1711 | 0.1184 | 0.0921 | 0.1316 | 0.1579 | 0.1711 | 0.1316 | 0.2105 | 0.1053 | 0.2237 | 0.0395 | 0.0921 | 0 | 0.0789 | 0.0395 | 0.0526 | 0.111 |
A liver function measurement (in U/L). Normal range is 8-48 IU/L. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | IU/L (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 29.122 | 28.014 | 30.148 | 27.196 | 29.86 |
| Arm II (Placebo) | 30.467 | 32.158 | 31.155 | 30.536 | 29.245 |
A liver function measurement (in U/L). Normal range is 14-20 for men, 10-36 for women. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | IU/L (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 26.608 | 24.068 | 25.426 | 24.375 | 24.561 |
| Arm II (Placebo) | 25.773 | 26.342 | 27.014 | 28.411 | 27.038 |
A liver function measurement (in mg/dL). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 0.5634 | 0.5973 | 0.563 | 0.593 | 0.5561 |
| Arm II (Placebo) | 0.4989 | 0.4942 | 0.4969 | 0.507 | 0.5449 |
N-terminal pro b-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | pg/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 85.6301 | 90.7536 | 87.7167 | 99.4912 | 101.8333 |
| Arm II (Placebo) | 115.7222 | 128.9565 | 115.6364 | 93.2105 | 107.849 |
Troponin I is a biomarker for myocardial cell injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 0.00446 | 0.00265 | 0.00467 | 0.00737 | 0.01111 |
| Arm II (Placebo) | 0.0011 | 0.00174 | 0.00742 | 0.00684 | 0.01132 |
The percentage of blood leaving the heart at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | Percent (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 57.6 | 58.16 | 58.07 | 57.35 | 58.16 |
| Arm II (Placebo) | 57.42 | 56.84 | 56.61 | 57.6 | 57.5 |
A measure to assess preload and afterload (in %). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | percent (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 28.5362 | 28.5409 | 29.6121 | 27.8219 | 28.0302 |
| Arm II (Placebo) | 28.4339 | 27.6866 | 28.1085 | 27.8891 | 28.5953 |
A protein produced by activated macrophages, and a member of a family of β-galactoside-binding lectings and promotes cardiac fibroblast proliferation and collagen synthesis following myocadial injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 4.4464 | 4.3252 | 3.7345 | 3.4548 | 3.8073 |
| Arm II (Placebo) | 5.2538 | 4.3735 | 4.3415 | 4.0214 | 4.0791 |
The amount of blood (in ml) in the heart's left ventricle just before the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 99.7507 | 99.3216 | 102.378 | 101.174 | 100.659 |
| Arm II (Placebo) | 93.3155 | 95.7434 | 96.5002 | 99.4656 | 98.9602 |
Thickness of cardiac muscle (in ml) of the left ventricle at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 4.5836 | 4.6035 | 4.636 | 4.6032 | 4.5147 |
| Arm II (Placebo) | 4.5269 | 4.565 | 0.0556 | 4.5462 | 4.5976 |
The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | centimeter (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 03.2765 | 3.2901 | 3.262 | 3.32 | 3.2441 |
| Arm II (Placebo) | 3.2396 | 3.3023 | 3.2964 | 3.2798 | 3.286 |
The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 42.2193 | 41.6128 | 42.8437 | 43.1453 | 42.0086 |
| Arm II (Placebo) | 39.7354 | 41.3839 | 41.8113 | 1.605 | 42.442 |
Echocardiographic measure of left ventricular (LV) afterload based on LV pressure (P), volume (V), and wall thickness (T), calculated by the formula (P x V)/T, which equals the number referred to below in the Measure Type. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | g/cm^2 (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 93.2892 | 90.3088 | 88.984 | 93.9267 | 89.2513 |
| Arm II (Placebo) | 90.6135 | 96.8356 | 96.0616 | 91.6458 | 94.0647 |
The weight of the left ventricle adjusted for body surface area (in g/m2). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | g/m2 (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 57.4862 | 58.2839 | 60.2116 | 57.7053 | 58.3315 |
| Arm II (Placebo) | 57.9322 | 57.0924 | 59.4508 | 59.1793 | 59.1026 |
Z-score of the ratio of left ventricular (LV) posterior wall dimension of systole to internal LV dimension in diastole, calculated for each subject by subtracting the reference healthy population mean, then dividing by the standard deviation. The Z-score indicates the number of standard deviations away from the mean of the reference population. Negative Z- score indicates worse outcome. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | z-score (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | -0.1372 | -0.2167 | -0.2416 | -0.2375 | 0.0213 |
| Arm II (Placebo) | -0.0893 | 0.3215 | -0.2367 | -0.1974 | 0.1834 |
B-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | pg/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 27.3836 | 31.8406 | 26.8203 | 35.807 | 34.625 |
| Arm II (Placebo) | 31.4324 | 34.1857 | 33.2941 | 32.2807 | 33.3774 |
"Ratio of peak velocity blood flow from left ventricular relaxation in early diastole (E wave) to peak velocity flow in late diastole caused by atrial contraction (A wave). Number shown for Unit of Measure refers to this ratio. Normal: >1. Impaired: <1. The mean is reported by arm at each timepoint with corresponding standard errors." (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ratio (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 1.728 | 1.642 | 1.723 | 1.732 | 1.603 |
| Arm II (Placebo) | 1.732 | 0.071 | 1.722 | 1.732 | 1.64 |
5 reviews available for carvedilol and Cardiotoxicity
| Article | Year |
|---|---|
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Topics: Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Antibiotics, Antineoplastic; Breast Neopl | 2022 |
Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
Topics: Anthracyclines; Antioxidants; Cardiotoxicity; Carvedilol; Heart Diseases; Humans; Neoplasms | 2018 |
Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antineoplastic Agents; Cardiotoxicity; Carvedilol; Echocar | 2019 |
Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Calcium Channel Blockers; Cardiotoxicity; Carvedilol; H | 2020 |
Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Carvedilol; | 2018 |
8 trials available for carvedilol and Cardiotoxicity
| Article | Year |
|---|---|
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Topics: Adrenergic beta-Antagonists; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardioto | 2023 |
Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled tria
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antibiotics, Antineoplastic; Antioxidants; Bio | 2020 |
Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antibiotics, Antineoplastic; Antihype | 2021 |
Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antineopla | 2017 |
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi | 2018 |
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi | 2018 |
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi | 2018 |
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi | 2018 |
Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Carbazoles; Cardi | 2016 |
Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk
Topics: Adrenergic beta-Antagonists; Age Factors; Anthracyclines; Antibiotics, Antineoplastic; Carbazoles; C | 2016 |
Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Atrial Function, Left; Biomarkers; Breast | 2017 |
14 other studies available for carvedilol and Cardiotoxicity
| Article | Year |
|---|---|
Pharmacological assessment of zebrafish-based cardiotoxicity models.
Topics: Animals; Cardiomyopathies; Cardiotoxicity; Carvedilol; Doxorubicin; Zebrafish | 2022 |
Carvedilol ameliorates dexamethasone-induced myocardial injury in rats independent of its action on the α1-adrenergic receptor.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiotoxicity; Carvedilol; Dexamethasone; Phenyle | 2022 |
Effect of Cardioprotective Drugs on Chemotherapy-Induced Heart Failure and New Risk Stratification.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedilol; Heart Failure; Humans; Lisinopr | 2019 |
Strategies to Prevent Cardiotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedilol; Humans; Lisinopril; Neoplasms; | 2019 |
In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Breast Neoplasms; Cardiotoxicity; Carved | 2020 |
Antioxidant, antiapoptotic, and antifibrotic effects of the combination of liposomal resveratrol and carvedilol against doxorubicin-induced cardiomyopathy in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Cardiomyopathies; Cardiotoxicity; Car | 2020 |
Umbilical cord blood-mesenchymal stem cells and carvedilol reduce doxorubicin- induced cardiotoxicity: Possible role of insulin-like growth factor-1.
Topics: Animals; Carbazoles; Cardiotoxicity; Carvedilol; Doxorubicin; Fetal Blood; Humans; Insulin-Like Grow | 2018 |
Can Carvedilol Prevent Chemotherapy-Related Cardiotoxicity?: A Dream to Be Balanced With Tolerability.
Topics: Cardiotoxicity; Carvedilol; Doxorubicin; Humans; Stroke Volume | 2018 |
Reply: Can Carvedilol Prevent Chemotherapy-Related Cardiotoxicity?: A Dream to Be Balanced With Tolerability.
Topics: Cardiotoxicity; Carvedilol; Doxorubicin; Humans; Stroke Volume | 2018 |
Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy.
Topics: Abietanes; Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Autophagy; Cardiotoxicity; | 2019 |
Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway.
Topics: Animals; Cadmium; Cardiotonic Agents; Cardiotoxicity; Carvedilol; Heme Oxygenase (Decyclizing); Male | 2019 |
Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy: End of One Size Fits All.
Topics: Breast Neoplasms; Cardiotoxicity; Carvedilol; Humans; Lisinopril; Trastuzumab | 2019 |
Protective Effects of Carvedilol and Vitamin C against Azithromycin-Induced Cardiotoxicity in Rats via Decreasing ROS, IL1-β, and TNF-α Production and Inhibiting NF-κB and Caspase-3 Expression.
Topics: Animals; Anti-Bacterial Agents; Ascorbic Acid; Azithromycin; Carbazoles; Cardiotoxicity; Carvedilol; | 2016 |
Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
Topics: Biomarkers; Breast Neoplasms; Carbazoles; Cardiotoxicity; Carvedilol; Doxorubicin; Female; Humans; M | 2017 |